- Co-promotion of cell therapy product for burns and diabetic foot ulcers
- Co-promotion of cell therapy product for burns and diabetic foot ulcers
SK chemicals has made the decision to cooperate with Tego Science, a cell therapy company, to sell cell therapy products for burns and diabetic foot ulcers.
SK chemicals (CEO Kwang-hyun Jeon) announced on the 14th that SK sciences has entered into a co-promotion agreement with Tego Science on the 13th (CEO Sae-hwa Jeon) to increase the domestic market share of Tego Science's Kaloderm through sales and marketing to larger hospitals beginning on the 1st of next month.
Through the co-promotion for Kaloderm, SK chemicals is expected to expand its portfolio into the area of diabetic complications. Equipped with SK chemicals’ excellent marketing capabilities, Tego Science looks forward to realizing synergy from the co-promotion, especially since insurance benefits were extended to diabetic foot ulcers, which expands the market.
Kaloderm is the most widely used cell therapy product in Korea and has been used in more than 400,000 cases since 2005. In 2019, insurance benefits were extended to cover treatments for burns and diabetic foot ulcers. Kaloderm is the only cell therapy product in Korea that provides insurance coverage for burns and diabetic foot ulcers.
In particular, unlike most other cell therapy products, Kaloderm can be mass-produced, stored frozen for long periods, and quickly supplied to patients when in need.
According to the Health Insurance Review and Assessment Service, the number of patients receiving medical treatment for diabetic foot ulcers in Korea reached 15,287 as of 2019, a 9.6% increase since 2015. Approximately 28% of patients suffering from diabetic foot ulcers must undergo amputation- a dangerous complication, given a survival rate of only 50% within a 5-year period.
Tego Sciences sales manager Lee Yun-ho remarked “Kaloderm is a new cell therapy drug developed with Tego Science's technology and is recognized in the domestic market for its excellent clinical value.” and “Based on SK chemicals’ marketing capabilities and know-how, it will rise to become the best cell therapy product.”
Jeong-hoon Kim, Head of Pharma R&D at SK chemicals, said “This co-promotion establishes another successful model of collaboration between domestic companies. To contribute to the promotion of national health, we plan to continuously expand our product portfolio in the surgical field and the field of complications from diabetes, which is one of the chronic diseases.”
![SK케미칼과 테고사이언스가 공동판매하기로 한 세포치료제 [칼로덤]](https://www.skchemicals.com/imgup/news/20210115_01.jpg)
# Photo: Cell therapy product will be sold under joint collaboration by SK chemicals and Tego Science.